Glucagon-like peptide-1 - Amylin

Drug Profile

Glucagon-like peptide-1 - Amylin

Alternative Names: AC 2592; GLP-1; GLP-1 - Amylin

Latest Information Update: 11 Mar 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amylin Pharmaceuticals
  • Class Glucagon-like peptides
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Diabetes mellitus; Heart failure

Most Recent Events

  • 29 Apr 2016 Biomarkers information updated
  • 05 Nov 2004 Amylin has begun its own phase II trial in congestive heart failure in the US (SC)
  • 31 Jul 2003 A study has been added to the adverse events and Heart Failure therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top